Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc To Discuss RGX-314 For The Treatment Of Wet AMD Call Transcript

Oct 03, 2022 / 12:30PM GMT
Release Date Price: $24.17 (-8.55%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the REGENXBIO Update Call on RGX-314 for the Treatment of wet AMD. (Operator Instructions)

I would now like to turn the call over to your host, Ken Mills, Chief Executive Officer. You may begin.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Good morning, everyone. Thanks for joining us so early. We're pleased this morning to be sharing new interim data from our Phase II AAVIATE trial of RGX-314 for the treatment of patients with wet AMD using suprachoroidal delivery.

Here on the call this morning to discuss the data are Dr. Steve Pakola, our Chief Medical Officer; Dr. Arshad Khanani, who will be joining us to share his thoughts and for Q&A. Dr. Khanani is an undisputed leader in the retina community and a strong advocate for patients. He's the Director of Clinical Research at Sierra Eye Associates, preeminent retinal surgeons and one of the clinical investigators involved in our RGX-314 clinical program. Throughout the call, you can follow along with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot